Trial Profile

Phase I/II study of AF802 in patients with Non-Small Cell Lung Cancer harboring ALK fusion gene

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alectinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Chugai Pharmaceutical

Most Recent Events

18 Oct 2017 Final efficacy and safety results of phase II part of study (n=46), presented at the 18th World Conference on Lung Cancer.
15 Mar 2017 Results of three year follow-up data of phase II part of this study (n=46) published in the Journal of Clinical Oncology
02 Jun 2015 Results of the phase II portion presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com